Portfolio company
Salarius Pharmaceutical
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops epigenetic therapeutics and peptide-conjugate treatments for patients with rare pediatric cancers and advanced solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Constellation Pharmaceuticals
This biopharmaceutical company develops small-molecule epigenetics therapies to treat patients with blood cancers and solid tumours.
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
Valius
This company develops molecular diagnostic platforms to identify therapeutic options for patients with rare and advanced cancers.
SpringWorks Therapeutics
This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.
Bellicum Pharmaceuticals
This company develops controllable cellular immunotherapies for patients with solid tumours and rare inherited blood cancers.
Shorla
This pharmaceutical company develops and manufactures innovative oncology drugs for patients with rare, paediatric and orphan cancers where existing treatments are inadequate.
Epics Therapeutics
This biotechnology company develops small-molecule RNA epigenetic modulators to treat patients with solid tumours and autoimmune diseases.
Epitome Therapeutics
This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.